Cystic Fibrosis, Healthy Volunteer
Conditions
Brief summary
This trial will consist of two parts: Part 1 and Part 2. Part 1 will enroll adult healthy volunteers (HV) into four treatment groups. The first group will enroll HV into a single ascending dose (SAD) treatment group consisting of three cohorts. The second group will enroll HV into a multiple ascending dose (MAD) treatment group consisting of three cohorts. The third group will enroll HV into a food effect (FE) treatment group consisting of one cohort. The fourth group will enroll HV into a drug-drug interactions (DDI) treatment group consisting of one cohort. Approximately 76 subjects will be enrolled in Part 1. Part 2 Cohorts 1 through 3 will enroll adult subjects with cystic fibrosis (CF) currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months. Part 2 Cohorts 4 and Cohort 5 will enroll adult subjects with CF not currently receiving cystic fibrosis conductance regulator (CFTR) modulator therapy within 30 days prior to Day 1. Part 2 Cohort 6 will enroll adult subjects with cystic fibrosis on stable tezacaftor/ivacaftor background therapy. Approximately 104 subjects will be enrolled in Part 2.
Detailed description
PART 1 The SAD treatment group is comprised of three cohorts where HV will be randomized to either PTI-801 or placebo. The MAD treatment group is comprised of three cohorts where subjects will be randomized to receive either PTI-801 or placebo once daily (QD) for a total of 7 days. HV will participate in a FE treatment group ,the FE treatment group is comprised of one cohort where subjects will be randomized to receive an initial single dose of PTI-801 either after an overnight fast of at least 10 hours (fasted group) or after an overnight fast of at least 10 hours followed by the consumption of a high fat high and high calorie meal (fed group). A set of HV will participate in a DDI treatment group. The DDI treatment group is comprised of one cohort where subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. PART 2 Part 2 is comprised of a MAD treatment group with three cohorts, a co-administration group with two cohorts and a treatment group with one cohort. Following the conclusion of the complementary HV MAD Cohort in Part 1, a set of adult subjects diagnosed with CF currently on a stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. Following the conclusion of CF MAD Cohort 1 in Part 2, a set of adult subjects diagnosed with CF not currently receiving or have received background CFTR modulator therapy for a minimum of 30 days prior to Day 1 will participate in the Part 2 CF PTI-801 and PTI-808 co-administration cohort. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD for a total of 14 days. Following the conclusion of the CF MAD Cohort 1 in Part 2, a set of adult subjects diagnosed with CF currently on a stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF cohort. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days.
Sponsors
Proteostasis Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Part 1 Inclusion Criteria: * Adults age 18 to 55 years old, inclusive, at the time of informed consent. * Body mass index (BMI) ≥18 to \<30 kg/m2. * Subject must be a nonsmoker and a nontobacco user for a minimum of 30 days prior to screening and for the duration of the study. Part 1
Exclusion criteria
* History or current evidence of any clinically significant cardiac, endocrinologic,hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic,dermatologic, psychiatric, renal, or other major disease, as determined by the investigator. * Presence of prolonged QT/ Corrected QT Interval (QTc) interval with Fridericia's correction formula (QTcF) \>450 msec at screening. * Abnormal liver function as defined by aspartate aminotransferase (AST), alanine aminotransferase (ALT) or bilirubin \> upper limit of the normal range. * Abnormal renal function at screening defined as: Creatinine clearance \<80 mL/min using the Cockcroft-Gault equation. * Participation in another clinical trial or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, prior to Study Day 1. * History of cancer within the past 5 years (excluding nonmelanoma skin cancer). * History or current evidence of alcohol or drug abuse or dependence within 12 months of screening as determined by the investigator. * Positive urine screen for prohibited drugs (cocaine, cannabinoids, nicotine \[urine cotinine is the detection mechanism for nicotine\], opiates, barbiturates, amphetamines, and benzodiazepines) or positive alcohol test at screening. * Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb). * Has donated blood within 3 months of screening or plans to donate blood within 3 months of study completion. Part 1 HV DDI Cohort Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 2 CF: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs | baseline through Day 21 | — |
| Part 1 SAD and MAD HV: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs | baseline to up to 14 days | — |
| Part 1 SAD: Apparent terminal half-life (t1/2) of single oral dose | through 72-hours post dose | — |
| Part 1 SAD: Time to reach maximum plasma concentration (Tmax) of single oral dose | through 72-hours post dose | — |
| Part 1 SAD: Maximum plasma concentration (Cmax) of single oral dose | through 72-hours post dose | — |
| Part 1 SAD: Area under the concentration-time curve from time 0 to 24 hours post administration (AUC0-24) of a single oral dose | through 72-hours post dose | — |
| Part 1 SAD: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-last) of a single oral dose | through 72-hours post dose | — |
| Part 1 SAD: AUC from time 0 to infinity (AUC0-inf) | through 72-hours post dose | using noncompartmental methods as appropriate of single dose |
| Part 1 MAD HV: Apparent terminal half-life (t1/2) of multiple oral doses | through 72-hours post last dose | — |
| Part 1 MAD HV: Time to reach maximum plasma concentration (Tmax) of multiple oral doses | through 72-hours post last dose | — |
| Part 1 MAD HV: Area under the concentration-time curve from time 0 to 24 hours post administration (AUC0-24) of multiple oral doses | through 72-hours post dose | — |
| Part 1 MAD HV: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) of multiple oral doses | through 72-hour post last dose | — |
| Part 1 MAD HV: AUC from time 0 to infinity (AUC0-inf) of multiple oral doses | through 72-hour post last dose | using noncompartmental methods as appropriate of multiple oral doses |
| Part 1 MAD HV: Cumulative amount of PTI-801 excreted unchanged in urine (Ae) as appropriate of multiple oral doses | through 24-hour post last dose | — |
| Part 1 MAD HV: Cumulative amount of PTI-801 unchanged in renal clearance (CLR) as appropriate of multiple oral doses | through 24-hour post last dose | — |
| Part 1 FE: Time to reach maximum plasma concentration (Tmax) | through 72-hour post last dose | — |
| Part 1 FE :Maximum plasma concentration (Cmax) | through 72-hour post last dose | — |
| Part 1 FE: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUCt) | through 72-hour post last dose | — |
| Part 1 FE: AUC from time 0 to infinity (AUC0-inf) | through 72-hour post last dose | — |
| Part 1 DDI: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs | baseline through 7 days post last dose | — |
| Part 1 DDI: Maximum plasma concentration (Cmax) of caffeine, bupropion, and midazolam with and without multiple oral doses of PTI-801 | through 72-hours post dose | — |
| Part 1 DDI: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) of caffeine, bupropion, and midazolam with and without multiple oral doses of PTI-801 | through 72-hours post dose | — |
| Part 1 DDI: Area under the concentration-time curve from time 0 to infinity (AUCinf) of caffeine, bupropion, and midazolam with and without multiple oral doses of PTI-801 | through 72-hours post dose | — |
| Part 1 MAD HV: Maximum plasma concentration (Cmax) of multiple oral doses | through 72-hours post last dose | — |
Secondary
| Measure | Time frame |
|---|---|
| Part 2 CF: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) | Day 1 through Day 15 |
| Part 1 DDI: Maximum plasma concentration (Cmax) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam | through 72-hours post dose |
| Part 1 DDI: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam | through 72-hours post dose |
| Part 2 CF: Time to reach maximum plasma concentration (Tmax) | Day 1 through Day 15 |
| Part 2 CF: Maximum plasma concentration (Cmax) | Day 1 through Day 15 |
| Part 2 CF: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) of multiple oral doses of PTI-808 with PTI-801 | Day 1 through Day 15 |
| Part 2 CF: change in forced expiratory volume in one second (FEV1) over time | baseline through Day 21 |
| Part 1 FE: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs | baseline through 7 days post last dose |
| Part 1 DDI: Apparent terminal half-life (t1/2) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam | through 72-hours post dose |
| Part 1 DDI: Time to reach maximum plasma concentration (Tmax) of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 | through 72-hours post dose |
| Part 1 DDI: Maximum plasma concentration (Cmax) of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 | through 72-hours post dose |
| Part 1 DDI: AUClast of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 | through 72-hours post dose |
| Part 1 DDI: Area under the concentration-time curve from time 0 to 24 hours post administration (AUC0-24) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam | through 72-hours post dose |
| Part 1 DDI: Metabolite over parent ratio of Cmax of single oral doses of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 | through 72-hours post dose |
| Part 1 DDI: Metabolite over parent ratio of AUClast of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 | through 72-hours post dose |
| Part 1 DDI: Time to reach maximum plasma concentration (Tmax) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam | through 72-hours post dose |
Other
| Measure | Time frame |
|---|---|
| Part 1: change in nasal epithelial mRNA and protein expression over time | baseline through 7 days post last dose |
| Part 2 CF: change in sweat chloride over time | baseline through Day 21 |
| Part 2 CF: change in nasal epithelial mRNA and protein expression over time | baseline through Day 21 |
| Part 2 CF: change in weight and BMI over time | baseline through Day 21 |
| Part 2 CF: change in blood glucose over time | baseline through Day 21 |
| Part 1 SAD, MAD HV, and FE: The effect of PTI-801 on the QT interval as measured by holter monitoring | baseline through 7 days post last dose |
Countries
Canada, Denmark, Germany, Sweden, United States
Outcome results
None listed